Welcome reset in health and medical insurance

FOR more than two decades, Malaysians have been sold medical protection that behaves like a financial product first and a health product second. Investment-linked policies (ILPs) were marketed as modern and flexible solutions or “one plan for everything”.

In truth, ILPs created a hidden structural problem: the sustainability of your medical coverage depended on whether the market performed, whether your fund value held, and whether you agree to pay more when projections fall apart.

This is all about to change as the Finance Ministry has confirmed that the government’s basic medical and health insurance scheme (MHIT), set to be introduced in early 2027, will be a standalone product not tied to investment performance, “Govt’s medical, health insurance scheme to be standalone product, says Finance Ministry” (The Star, Dec 5).

This is not a tweak; it is a long overdue policy correction that will force the industry to confront a question it has avoided for years: Why was health protection in Malaysia allowed to sit inside a vehicle whose performance rested on market volatility?

The ILP model was built on optimistic assumptions, steady investment gains, stable charges and decades of smooth fund performance. But when returns fell short, the entire design began to wobble. Policyholders were told their accounts were draining, their premiums were no longer sufficient, or their coverage might expire long before the policy term. Many only then realised they had been paying for a medical plan whose survival depended on stock markets.

A standalone basic MHIT product is the clean break Malaysia needs. It removes the false promise that an investment-linked plan can comfortably carry long-term medical inflation. It also forces insurers to price protection transparently, not bury charges inside a fund structure few consumers truly understand.

And it gives policyholders exactly what they thought they were buying all along: medical coverage that lasts as long as the premiums are paid without the added risk of market turbulence.

Bank Negara Malaysia’s review of ILP medical riders is equally significant. It signals that the regulator understands the structural flaws, not just the sales problems.

The industry has often pointed to “misunderstandings” or “communication issues” when policyholders face lapses or top-ups. But the issue is deeper: the product architecture itself generates complexity, and complexity inevitably leads to poor comprehension.

Tighter disclosures, stricter projections and clear sustainability updates are necessary, but they cannot fix the core mismatch between medical costs and investment-linked structures. The basic MHIT product does.

Still, this reform won’t solve the underlying problem policymakers quietly worry about: the relentless rise of medical costs.

Malaysia’s private healthcare prices are climbing faster than wages, and out-of-pocket pressure on households is growing. Even with a standalone product, premiums will rise because the real forces – hospital charges, specialist fees, pharmaceuticals, demographic ageing, etc. – will continue marching upward.

The basic MHIT product does not flatten medical inflation, but it removes the illusion that fund performance could soften the blow. And when the illusion disappears, conversations about healthcare costs become more honest.

Malaysia’s insurance industry is now being asked to return to first principles. Medical insurance must be predictable; it must be priced honestly; and it must not rely on investment returns to remain afloat.

The basic MHIT product is a reset, one that brings us closer to a system where protection means protection, not projection.

The government’s move to make the basic MHIT product fully standalone is the clearest signal yet that the era of hiding medical coverage inside investment-linked wrappers is coming to an end. And not a moment too soon.

WONG TECK JIN

Petaling Jaya